(Ovarian Cancer) Is Tislelizumab + Sitravatinib Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- March 30, 2020
- Read time: 1 minute
From December 11–14, 2019, at the European Society for Medical Oncology Immuno-Oncology Congress held in Geneva, Switzerland, Bo Gao presented "Efficacy and safety results of anti-PD-1 antibody drug tislelizumab + sitravatinib in platinum-resistant ovarian cancer patients in a Phase 1b clinical trial."
The Phase 1b clinical trial enrolled platinum-resistant ovarian cancer patients (N=20) and administered tislelizumab 200 mg + sitravatinib 120 mg once daily on a 3-week cycle. The primary endpoint was safety; secondary endpoints were objective response rate, duration of response, and progression-free survival.
Grade 3 or higher adverse events related to sitravatinib confirmed in more than 10% of patients included: hypertension 25% and fatigue 10%. Grade 3 or higher adverse events related to tislelizumab included: ALT elevation 10%. The number of patients who discontinued treatment due to adverse events was: sitravatinib — 6 patients / tislelizumab — 3 patients.
Of the 20 patients enrolled, 17 were evaluated as having a response. Of these, 4 achieved partial response, 11 had stable disease, and 2 had disease progression. The median duration of response was not reached; the median progression-free survival was 18.0 weeks.
Based on the Phase 1b trial results, Bo Gao concluded: In platinum-resistant ovarian cancer patients, the combination of tislelizumab + sitravatinib demonstrated acceptable tolerability to adverse events along with promising antitumor activity.
[Important Note] Medical Supporter's translations of overseas clinical trial data and pharmaceutical information are not intended to encourage participation in clinical trials or use of new drugs. The translated information is for reference only and not intended as medication guidelines. Please discuss with healthcare professionals and refer to the original text below the article for accurate information.
Source: Sitravatinib Plus Tislelizumab Show Promise in Platinum-Resistant Advanced Ovarian Cancer (ESMO Immuno-Oncology Congress 2019, News & Press Releases)
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4